DK1730197T3 - Fremgangsmåde til fremkaldelse af autolyse i infektiøse bakterier - Google Patents

Fremgangsmåde til fremkaldelse af autolyse i infektiøse bakterier

Info

Publication number
DK1730197T3
DK1730197T3 DK05729289.8T DK05729289T DK1730197T3 DK 1730197 T3 DK1730197 T3 DK 1730197T3 DK 05729289 T DK05729289 T DK 05729289T DK 1730197 T3 DK1730197 T3 DK 1730197T3
Authority
DK
Denmark
Prior art keywords
infection
treatment
bacteria
infectious bacteria
autolysis
Prior art date
Application number
DK05729289.8T
Other languages
English (en)
Inventor
Keith Alan Charlton
Andrew Justin Radcliffe Porter
Ian Broadbent
Original Assignee
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd filed Critical Haptogen Ltd
Application granted granted Critical
Publication of DK1730197T3 publication Critical patent/DK1730197T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05729289.8T 2004-03-27 2005-03-24 Fremgangsmåde til fremkaldelse af autolyse i infektiøse bakterier DK1730197T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0407008.2A GB0407008D0 (en) 2004-03-27 2004-03-27 Methods for inducing rapid cell death (autolysis) in infectious bacteria
PCT/GB2005/001108 WO2005094883A2 (en) 2004-03-27 2005-03-24 Methods for inducing autolysis in infectious bacteria

Publications (1)

Publication Number Publication Date
DK1730197T3 true DK1730197T3 (da) 2012-06-25

Family

ID=32188889

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05729289.8T DK1730197T3 (da) 2004-03-27 2005-03-24 Fremgangsmåde til fremkaldelse af autolyse i infektiøse bakterier

Country Status (14)

Country Link
US (3) US20070218058A1 (da)
EP (2) EP1730197B1 (da)
JP (2) JP5167466B2 (da)
KR (2) KR20070050865A (da)
CN (1) CN1934134B (da)
AT (1) ATE548390T1 (da)
AU (1) AU2005227666B2 (da)
CA (1) CA2558435A1 (da)
DK (1) DK1730197T3 (da)
ES (1) ES2381374T3 (da)
GB (1) GB0407008D0 (da)
NO (1) NO20063871L (da)
SG (1) SG151316A1 (da)
WO (1) WO2005094883A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528935B1 (en) * 2002-08-13 2012-03-21 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
JP5170403B2 (ja) * 2008-03-14 2013-03-27 国立大学法人 筑波大学 細菌の増殖を制御する化合物及びその応用
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
US10472326B2 (en) * 2014-04-03 2019-11-12 Helmholtz-Zentrum für Infektionsforschung GmbH PQSR modulators
EP3502095A1 (en) * 2017-12-22 2019-06-26 Universität Konstanz Compound for use against pathogenic neisseria and haemophilus species and moraxella catarrhalis
CN108513984B (zh) * 2018-04-14 2020-12-29 华南农业大学 Ahl分子作为化学农药杀菌增效剂在黄单胞杆菌引起的黑腐病防治中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
EP1666058B1 (en) 1998-11-25 2011-12-28 MCW Research Foundation, Incorporated Method of diagnosing a Pseudomonas aeruginosa infection
GB9924195D0 (en) 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0007588D0 (en) 2000-03-30 2000-05-17 Univ Nottingham N-Acyl homoserine lactones
US6703513B1 (en) * 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
EP1528935B1 (en) * 2002-08-13 2012-03-21 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria

Also Published As

Publication number Publication date
JP2007530649A (ja) 2007-11-01
US20130011400A1 (en) 2013-01-10
US20070218058A1 (en) 2007-09-20
AU2005227666A1 (en) 2005-10-13
KR20070050865A (ko) 2007-05-16
ES2381374T3 (es) 2012-05-25
EP1730197A2 (en) 2006-12-13
AU2005227666B2 (en) 2011-09-01
US20110027280A1 (en) 2011-02-03
HK1099316A1 (en) 2007-08-10
CN1934134A (zh) 2007-03-21
SG151316A1 (en) 2009-04-30
EP1730197B1 (en) 2012-03-07
CN1934134B (zh) 2012-01-11
KR20130001741A (ko) 2013-01-04
EP2261260A2 (en) 2010-12-15
GB0407008D0 (en) 2004-04-28
JP2013040191A (ja) 2013-02-28
WO2005094883A3 (en) 2006-01-12
CA2558435A1 (en) 2005-10-13
EP2261260A3 (en) 2011-01-05
ATE548390T1 (de) 2012-03-15
WO2005094883A2 (en) 2005-10-13
JP5167466B2 (ja) 2013-03-21
NO20063871L (no) 2006-08-30

Similar Documents

Publication Publication Date Title
Minden-Birkenmaier et al. Honey-based templates in wound healing and tissue engineering
Tomb et al. New proof-of-concept in viral inactivation: virucidal efficacy of 405 nm light against feline calicivirus as a model for norovirus decontamination
Davis et al. Effectiveness of a polyhexanide irrigation solution on methicillin‐resistant Staphylococcus aureus biofilms in a porcine wound model
Kumar et al. COVID-19: environment concern and impact of Indian medicinal system
Bonamonte et al. Aquarium-borne Mycobacterium marinum skin infection. Report of 15 cases and review of the literature
BR0209057A (pt) Composições herbicidas contendo benzoilciclohexanodionas e protetores
EP2494059A4 (en) USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY
EA200201012A1 (ru) Способы стерилизации биологических материалов
Dauvergne et al. Brass alloys: copper-bottomed solutions against hospital-acquired infections?
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
Khokhar et al. Viricidal treatments for prevention of coronavirus infection
Gupta et al. Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichophyton mentagrophytes using an in vitro test system
NO20066005L (no) Injiserbar farmasoytisk suspensjon omfattende posaconazol
DK1730197T3 (da) Fremgangsmåde til fremkaldelse af autolyse i infektiøse bakterier
NO20076405L (no) Anvendelse av 24-nor-UDCA
Al-Dahmoshi et al. Molecular detection of some virulence traits among Pseudomonas aeruginosa isolates, Hilla-Iraq
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
Parvin et al. Efficacy of surgical/wound washes against bacteria: effect of different in vitro models
Glass et al. The effectiveness of a uv toothbrush sanitizing device in reducing the number of bacteria, yeasts and viruses on toothbrushes.
Geraldes et al. Biocides in the hospital environment: Application and tolerance development
Stibich et al. The microbiological impact of pulsed xenon ultraviolet disinfection on resistant bacteria, bacterial spore and fungi and viruses
EP1639971A4 (en) COMPOSITIONS FOR SKIN PROTECTION
ATE479430T1 (de) Verwendung von retinoid-typ verbindungen als antibakterielle mittel gegen staphylococcus aureus
Pani et al. Phenotypic heterogeneity in bacteria: the rise of antibiotic persistence, clinical implications, and therapeutic opportunities
Ghosh et al. Traditional medicine in the management of microbial infections as antimicrobials: Pros and cons